Akorn (Nasdaq: AKRX) reported earnings on Aug. 7. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended June 30 (Q2), Akorn beat expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue increased significantly and GAAP earnings per share dropped significantly.

Gross margins increased, operating margins grew, net margins dropped.

Revenue details
 Akorn recorded revenue of $63.3 million. The five analysts polled by S&P Capital IQ wanted to see sales of $60.6 million on the same basis. GAAP reported sales were 97% higher than the prior-year quarter's $32.1 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.10. The three earnings estimates compiled by S&P Capital IQ forecast $0.09 per share. GAAP EPS of $0.10 for Q2 were 41% lower than the prior-year quarter's $0.17 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 56.5%, 90 basis points better than the prior-year quarter. Operating margin was 30.0%, 920 basis points better than the prior-year quarter. Net margin was 16.7%, 3,910 basis points worse than the prior-year quarter.

Looking ahead
 Next quarter's average estimate for revenue is $67.9 million. On the bottom line, the average EPS estimate is $0.11.

Next year's average estimate for revenue is $251.2 million. The average EPS estimate is $0.40.

Investor sentiment
 The stock has a three-star rating (out of five) at Motley Fool CAPS, with 166 members out of 179 rating the stock outperform, and 13 members rating it underperform. Among 43 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 36 give Akorn a green thumbs-up, and seven give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Akorn is outperform, with an average price target of $15.00.